Liangqing Holdings (08603) plans to be listed on the main board

Zhitong Finance App News, Liangqing Holdings (08603) issued an announcement. The company submitted a transfer listing application to the Stock Exchange in accordance with Chapter 9B of the Main Board Listing Rules on December 8, 2025. The transfer listing will not involve the issuance of any new shares by the Company.

The board of directors believes that with the main board's large total market value, high trading volume and relatively high international popularity, the transfer from GEM to the main board listing will greatly enhance the company's corporate image and public recognition. As a mature medical aesthetic service provider in Hong Kong, the Group believes that the stricter listing requirements of the main board and the high quality position it represents are a strong recognition of its operating performance and market position. This increase in reputation is expected to enhance the company's ability to attract and retain high-quality customers, business partners and talents, while also helping to seize new business opportunities more effectively.

On the other hand, the board of directors believes that the main board listing will broaden the company's access to a wider range of investors, including institutional investors, professional investors and international participants, thereby expanding and diversifying the shareholder base. This transfer listing is also expected to enhance the company's financing flexibility, enabling it to obtain more diversified debt financing options on more favorable terms. This move will support the optimization of capital structures and provide space for more strategic financial management. The board of directors believes that the transfer listing will have a positive effect on the Group's sustainable growth and long-term development, thereby consolidating its leading position in the field of medical aesthetics and creating lasting value for the company and its shareholders.

The board of directors believes that the transfer listing will have a positive effect on the Group's sustainable growth and long-term development, thereby consolidating its leading position in the field of medical aesthetics and creating lasting value for the company and its shareholders.